Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings.

One hundred ten of 175 patients with aplastic anemia conditioned by cyclophosphamide had sustained engraftment of marrow from human leukocyte antigen (HLA)-identical siblings and lived for more than 6 months. Forty-nine of the 110 patients developed chronic graft-versus-host disease between 85 and 464 days. Ninety-seven patients are alive from 1.4 to 11 years after engraftment; 13 died between 208 and 726 days. Twenty of the 36 surviving patients with chronic graft-versus-host disease have Karnofsky performance scores of 100%, 7 of 90%, 5 of 80%, 1 of 70%, 2 of 60%, and 1 of 40%. Our analysis, using a binary logistic regression model, identified three factors predicting chronic graft-versus-host disease: moderate to severe acute graft-versus-host disease with an estimated relative risk of 11.65; increasing patient age; and the use of viable donor buffy coat cells in addition to the marrow to prevent graft rejection. The last two factors were significant only in patients without acute graft-versus-host disease.

[1]  K. Sullivan,et al.  Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. , 1983, The New England journal of medicine.

[2]  K. Sullivan,et al.  Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. , 1982, Blood.

[3]  K. Sullivan,et al.  Marrow transplantation with or without donor buffy coat cells for 65 transfused aplastic anemia patients , 1982 .

[4]  H. Ochs,et al.  Thymus transplantation after allogeneic bone marrow graft to prevent chronic graft-versus-host disease in humans. , 1982, Transplantation.

[5]  R. Storb,et al.  Sequential studies of cell inhibition of host fibroblasts in 51 patients given HLA-identical marrow grafts. , 1982, Journal of immunology.

[6]  R. Storb,et al.  In vitro regulation of immunoglobulin synthesis after marrow transplantation. I. T-cell and B-cell deficiencies in patients with and without chronic graft-versus-host disease. , 1981, Blood.

[7]  K. Sullivan,et al.  Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment , 1981 .

[8]  R. Storb,et al.  Specific suppressor cells in graft–host tolerance of HLA-identical marrow transplantation , 1981, Nature.

[9]  R. Storb,et al.  Specific suppressor cells and immune response to host antigens in long-term human allogeneic marrow recipients: implications for the mechanisms of graft-host tolerance and chronic graft-versus-host disease. , 1981, Transplantation proceedings.

[10]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[11]  R. Storb,et al.  Cell-mediated immunity to non-HLA antigens of the host by donor lymphocytes in patients with chronic graft-vs-host disease. , 1980, Journal of immunology.

[12]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[13]  H. Deeg,et al.  In vitro tests correlating with presence or absence of graft-vs-host disease in DLA nonidentical canine radiation chimeras: evidence that clonal abortion maintains stable graft-host tolerance. , 1980, Journal of immunology.

[14]  H. Deeg,et al.  Marrow Transplantation in Thirty "Untransfused" Patients with Severe Aplastic Anemia , 1980, Annals of Internal Medicine.

[15]  R. Storb,et al.  Nonspecific suppressor cells in patients with chronic graft-vs-host disease after marrow grafting. , 1979, Journal of immunology.

[16]  R. Gale,et al.  Chronic graft versus host disease: a syndrome of disordered immunity. , 1979, The American journal of medicine.

[17]  K. Sullivan,et al.  Analysis of late infections in 89 long-term survivors of bone marrow transplantation. , 1979, Blood.

[18]  K. Sullivan,et al.  Chronic cutaneous graft-versus-host disease in man. , 1978, The American journal of pathology.

[19]  H. Ochs,et al.  Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. , 1978, Blood.

[20]  A. Gratwohl,et al.  Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease. , 1977, Annals of internal medicine.

[21]  M. Siimes,et al.  SCLERODERMA-LIKE GRAFT-VERSUS-HOST DISEASE AS LATE CONSEQUENCE OF BONE-MARROW GRAFTING , 1977, The Lancet.

[22]  I. Gigli,et al.  Graft-versus-host reaction. Cutaneous manifestations following bone marrow transplantation. , 1977, Archives of dermatology.

[23]  R. Storb,et al.  Treatment of aplastic anemia by marrow transplantation from HLA identical siblings. Prognostic factors associated with graft versus host disease and survival. , 1977, The Journal of clinical investigation.

[24]  Clift,et al.  Aplastic anemia treated by allogeneic bone marrow transplantation: a report on 49 new cases from Seattle. , 1976, Blood.

[25]  J. Streilein,et al.  Graft-versus-Host reactions: a review. , 1976, Advances in immunology.

[26]  J. Saurat,et al.  Graft versus host reaction and lichen planus‐like eruption in man , 1975, The British journal of dermatology.

[27]  J. Bach,et al.  ISOLATION, BIOCHEMICAL CHARACTERISTICS, AND BIOLOGICAL ACTIVITY OF A CIRCULATING THYMIC HORMONE IN THE MOUSE AND IN THE HUMAN , 1975, Annals of the New York Academy of Sciences.

[28]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[29]  P. Neiman,et al.  Allogeneic marrow grafting for treatment of aplastic anemia. , 1974, Blood.

[30]  D. van der Waaij,et al.  Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. , 1974, Journal of the National Cancer Institute.

[31]  E. Kohne,et al.  MORTALITY OF SECONDARY DISEASE IN ANTIBIOTIC-TREATED MOUSE RADIATION CHIMERAS , 1973 .

[32]  P. Neiman,et al.  Aplastic anaemia treated by marrow transplantation. , 1972, Lancet.

[33]  J. Jones,et al.  Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. , 1971, Radiation research.

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .